Clinical trials
Chidamide clinical trials
Below are recruiting chidamide clinical trials, each written for real people, not researchers. We’re tracking 67 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07074457Recruiting
Study of two drugs for CD30+ T-cell lymphoma
This trial tests a combination of two targeted drugs, chidamide and brentuximab vedotin, for people with a type of T-cell lymphoma that has the CD30 protein. It is for patients who are older or not healthy enough for standard chemotherapy, and whose cancer has come back or not responded to previous treatment.
Suzhou, JiangsuAges 18–75 - NCT07493148RecruitingPhase 2
Chidamide and chemo for older adults with double-expressor DLBCL
This trial tests a combination of the targeted drug chidamide with a gentler chemotherapy (R-mini CHOP) followed by maintenance therapy for people aged 70 or older with a specific type of DLBCL that has both MYC and BCL2 proteins. It aims to improve outcomes while reducing side effects.
Changchun, JilinAges 70 years+ - NCT05572983RecruitingPhase 2
New treatment for a specific T-cell lymphoma type
This Phase 2 trial tests chidamide plus CHOP chemotherapy in people who have not received any prior treatment for a certain type of peripheral T-cell lymphoma. The study aims to shrink the lymphoma and improve outcomes while checking for side effects and safety.
Guangzhou, GuangdongAges 18–75 - NCT06122389RecruitingPhase 3
Study of SHR2554 for T-cell lymphoma
This trial tests a new drug called SHR2554 (compared to chidamide) for T-cell lymphoma that has not responded to or come back after prior treatment. It's a Phase 3 study to see if the drug can help control the cancer.
Beijing, Beijing MunicipalityAges 18–70 - NCT06891157RecruitingPhase 2
A new combination treatment for a type of lymphoma
This trial tests adding chidamide to standard chemotherapy (R-CHOP) for people newly diagnosed with a specific subtype of diffuse large B-cell lymphoma. It may help improve outcomes for those whose cancer cells have high levels of MYC and BCL2 proteins.
Nanjing, JiangsuAges 18 years+ - NCT07754890RecruitingPhase 1/Phase 2
Study of two drugs for advanced skin lymphoma
This trial tests two medications (golidocitinib and chidamide) for people with a type of lymphoma that affects the skin. The combo may help control the disease when other treatments haven't worked or have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT06393361RecruitingPhase 2
Combination therapy for relapsed Hodgkin lymphoma without transplant
This trial tests a combination of two oral targeted drugs (chidamide and decitabine) plus an immunotherapy drug (anti-PD-1 antibody) for people with classical Hodgkin lymphoma that has not responded to at least two prior treatments and who cannot or choose not to have a stem cell transplant. The goal is to see if this three-drug combination can shrink tumors and help control the disease.
BeijingAges 18–75 - NCT05967949Recruiting
Chidamide maintenance after PTCL first treatment
This study looks back at people with PTCL who, after their initial first treatment, received chidamide as a continuing (maintenance) therapy. It aims to understand how effective and tolerated this approach may be in real-world care.
Nanjing, JiangsuAges 18 years+ - NCT05881265RecruitingPhase 2
Chidamide plus venetoclax for hard-to-treat APL
This trial studies chidamide and venetoclax in people with a specific type of acute promyelocytic leukemia (APL) that has not responded to standard treatment with all-trans retinoic acid (RA) plus arsenic. It may help by testing a new combination for cases in “non-remission” status.
Huai'an, JiangsuAges 16–70 - NCT05088226RecruitingPhase 2
Ruxolitinib plus chidamide before transplant for high-risk leukemia
This Phase 2 study tests whether adding two medicines (ruxolitinib and chidamide) to a “conditioning regimen” before an allogeneic stem cell transplant improves outcomes for people with high-risk B-cell ALL. It may help prepare the body for transplant and reduce the chance of leukemia coming back.
Beijing, Beijing MunicipalityAges 12–65 - NCT06930118RecruitingPhase 2
Study of 4 drugs for advanced colorectal cancer
This trial tests a combination of four drugs for people with advanced colorectal cancer who have already tried at least two other treatments. The goal is to see if this new mix can help shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT07518602RecruitingPhase 2
Chidamide, Sintilimab, and Bevacizumab for Advanced Neuroendocrine Cancer
This trial tests a combination of three drugs—chidamide (a protein regulator), sintilimab (an immune-boosting antibody), and bevacizumab (a growth-blocking antibody)—for patients with advanced neuroendocrine cancer that has spread or cannot be removed surgically and has progressed despite an initial treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
Guangzhou, GuangdongAges 18–75 - NCT07168317RecruitingPhase 2
Study of tislelizumab plus other drugs for new AITL lymphoma
This trial tests a combination of five drugs for people newly diagnosed with a rare type of lymphoma called angioimmunoblastic T-cell lymphoma (AITL). The goal is to see if this treatment helps control the cancer.
Xuzhou, JiangsuAges 18 years+ - NCT07545967RecruitingPhase 1
Re-radiation and Chidamide for Recurrent Head and Neck Cancer
This trial tests combining re-radiation (radiation therapy given a second time) with a drug called chidamide to treat head and neck cancer that has come back after previous radiation. The goal is to see if this combination can help patients whose cancer cannot be removed by surgery or who cannot have surgery.
Chengdu, SichuanAges 18–75 - NCT06570447RecruitingPhase 2
Glofitamab and chidamide for relapsed or refractory DLBCL
This trial tests a combination of two drugs, glofitamab and chidamide, for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded after at least two prior treatments. The goal is to see if this combination can help when other options have stopped working.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05890287Recruiting
Chidamide plus hormone therapy after chemotherapy for breast cancer
This trial studies chidamide added to standard hormone (endocrine) therapy to help prevent breast cancer from coming back after initial chemotherapy. It may help by keeping cancer under control for longer in people with HR-positive, HER2-negative breast cancer who respond to first-line treatment.
TianjinAges 18–75 - NCT07058103RecruitingPhase 2
Combination therapy for relapsed or refractory angioimmunoblastic T-cell lymphoma
This trial tests a combination of five drugs (tislelizumab, cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone) for patients with angioimmunoblastic T-cell lymphoma (AITL) that has come back or not responded to previous treatment. The goal is to see if this combination can shrink tumors or stop the disease from growing.
Xuzhou, JiangsuAges 18 years+ - NCT06685276RecruitingPhase 2
Combination therapy for advanced colorectal cancer
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
BeijingAges 18–75 - NCT07397832RecruitingPhase 2
CRP drug combo for older adults with untreated double-positive DLBCL
This trial tests a new combination of drugs (CRP regimen) for older patients who have not yet been treated for a specific type of DLBCL called double-expressor lymphoma. It aims to see if this combination is effective and safe for people who may not be able to get standard chemotherapy.
Tianjin, Tianjin MunicipalityAges 60 years+ - NCT04025450RecruitingPhase 1/Phase 2
Tested stronger combo for high-risk myeloma patients
This early-phase study compares two drug combinations—chidamide plus VRD versus VRD alone—to see which works better for primary high-risk multiple myeloma. The goal is to improve response while closely monitoring side effects and heart/lung safety.
Suzhou, JiangsuAges 18–80 - NCT05270200RecruitingPhase 1/Phase 2
Azacitidine and chidamide after transplant to prevent AML relapse
This trial tests two medicines given after a bone-marrow transplant to help lower the chance of acute myeloid leukemia (AML) coming back. It is aimed at people with higher-risk AML and checks safety along with whether the medicines can help prevent relapse.
Guanzhou, GuandongAges 18–60 - NCT05305859RecruitingPhase 2
Venetoclax, chidamide, and azacitidine for hard-to-treat AML
This Phase 2 trial tests whether adding three medicines—venetoclax, chidamide, and azacitidine—can help adults whose AML has come back or did not respond to treatment. It may help shrink or control the leukemia and improve outcomes for people who fit the study’s health and lab requirements.
Xiamen, FujianAges 18 years+ - NCT05566054RecruitingPhase 2
Newly diagnosed AML-M5 treated with VAC drug combination
This Phase 2 trial studies a combination of Venetoclax, Azacitidine, and Chidamide (VAC) for newly diagnosed acute monocytic leukemia (AML-M5). It may help people who cannot safely receive standard “intensive chemotherapy” because of age or other health problems.
Suzhou, JiangsuAges 18 years+ - NCT05682755RecruitingPhase 1/Phase 2
Chidamide to Prevent AML Return After Bone Marrow Transplant
This Phase 1/2 study tests whether chidamide can help prevent high-risk acute myeloid leukemia (AML) from coming back after an allogeneic bone marrow transplant (allo-HSCT). Participants must already be in complete remission and have recovered blood counts after transplant.
Chengdu, SichuanAges 18–65
Hear when a new Chidamide trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chidamide?
- Yes. Clin2 currently lists 67 recruiting chidamide studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chidamide trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chidamide trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.